Biopharma is reshaping healthcare with therapies that expand access and reshape how drugs are developed. Across today’s pipelines, decentralization is rising (17% of trials in 2023 added these elements) and biomarker-led design is shaping oncology studies (31% used biomarkers for patient selection). Alongside these clinical shifts, investment and manufacturing scale—such as US biopharma VC deal value totaling $50.0B in 2024 (Q1–Q3)—are helping drive momentum.
Key Takeaways
- $527.8 billion global biologics market size forecast for 2030
- 4.5% CAGR expected for the global biopharmaceuticals market through 2032 (Fortune Business Insights forecast)
- $250.0 billion global gene therapy market size in 2023
- $10.5 billion global biopharma M&A disclosed value in 2023
- $50.0 billion US biopharma VC deal value in 2024 (Q1-Q3 combined, per PitchBook summary)
- 17% of biopharma clinical trials added decentralization elements in 2023 (CTIS/ClinicalTrials.gov analysis)
- FDA approved 50 biosimilar biological products in 2023 (total biosimilar approvals)
- 2024 US biosimilars had 4,200+ total biosimilar product approvals (licensed biosimilar products; cumulative count through 2024, FDA data summary)
- In 2022/2023, the top 20 CDMOs reported capacity expansions of 18% (additional biologics manufacturing capacity additions across the cohort)
- 2023 global sterile injectable fill-finish market capacity growth was 9% year over year (industry market sizing by trade research group)
- 12.0% year-over-year growth in biopharma R&D headcount in the US in 2024
- 18.8% of total R&D spending at US pharmaceutical and medicine manufacturing firms in 2022 was devoted to biotechnology R&D
- 24.5% of FDA CDER novel drug approvals in 2023 were small-molecule drugs (comparator category share)
Biopharma is accelerating fast, with strong growth in biologics, gene and mRNA markets, and rising investment.
Related reading
01 · Category
Market Size13 stats
01
$527.8 billion global biologics market size forecast for 2030
02
4.5% CAGR expected for the global biopharmaceuticals market through 2032 (Fortune Business Insights forecast)
03
$250.0 billion global gene therapy market size in 2023
04
$8.96 billion global mRNA market size in 2023
05
$122.8 billion global monoclonal antibodies market size forecast for 2030
06
$60.0 billion global orphan drug market size in 2023
07
16.1% average annual growth in global biopharma R&D spend 2018-2023 (peer-reviewed analysis)
08
$54.2 billion global CDMO market size forecast for 2030 (biologics)
09
$17.0 billion US biosimilars market size in 2023 (estimate)
10
$27.0 billion forecast for US biosimilars market size in 2030
11
$3.2 billion global FDA biosimilar approvals cumulative through 2024 (FDA)
12
29% of all FDA CDER novel drug approvals in 2023 were biologics/biotechnology-derived products
13
37.2% of the $X (biotech/biopharma) sector R&D spend in the US was in vaccines and biologics-related activities in 2022
Interpretation
Market Size Interpretation
The market size outlook is expanding across key biopharma segments, with the global biologics market forecast to reach $527.8 billion by 2030 and the global biopharmaceuticals market growing at a 4.5% CAGR through 2032, alongside major segment scales like $250.0 billion in gene therapy and $60.0 billion in orphan drugs in 2023.
02 · Category
Industry Trends8 stats
01
$10.5 billion global biopharma M&A disclosed value in 2023
02
$50.0 billion US biopharma VC deal value in 2024 (Q1-Q3 combined, per PitchBook summary)
03
17% of biopharma clinical trials added decentralization elements in 2023 (CTIS/ClinicalTrials.gov analysis)
04
31% of oncology trials used biomarkers for patient selection in 2023 (peer-reviewed analysis)
05
$1.7 billion global spending on CDMO services for biologics in 2023
06
5,000+ biologic clinical trials were registered on ClinicalTrials.gov in 2023
07
18.7% of US pharmaceutical industry R&D spending in 2022 went to biologics/manufacturing technologies (NSF)
08
In 2023, 76% of sponsors reported using real-world evidence (RWE) in some form during drug development (survey-based metric)
Interpretation
Industry Trends Interpretation
Industry Trends are being shaped by dealmaking and innovation together, with $10.5 billion in 2023 biopharma M&A disclosed value and a strong research shift toward more targeted and decentralized studies, including 17% of clinical trials adding decentralization elements in 2023 and 31% of oncology trials using biomarkers for patient selection.
03 · Category
Manufacturing & Supply2 stats
01
In 2022/2023, the top 20 CDMOs reported capacity expansions of 18% (additional biologics manufacturing capacity additions across the cohort)
02
2023 global sterile injectable fill-finish market capacity growth was 9% year over year (industry market sizing by trade research group)
Interpretation
Manufacturing & Supply Interpretation
For the Manufacturing and Supply side of biopharma, the sector is scaling fast, with the top 20 CDMOs adding 18% more biologics manufacturing capacity in 2022 to 2023 while global sterile injectable fill finish capacity grew 9% year over year in 2023.
More related reading
04 · Category
R&d And Innovation2 stats
01
12.0% year-over-year growth in biopharma R&D headcount in the US in 2024
02
18.8% of total R&D spending at US pharmaceutical and medicine manufacturing firms in 2022 was devoted to biotechnology R&D
Interpretation
R&d And Innovation Interpretation
In the R and D and Innovation landscape, biopharma R and D headcount in the US grew 12.0% year over year in 2024, while biotechnology accounted for 18.8% of total R and D spending by US pharmaceutical and medicine manufacturing firms in 2022, signaling both expanding workforce commitment and a strong biotech focus.
05 · Category
Regulatory Milestones1 stats
01
FDA approved 50 biosimilar biological products in 2023 (total biosimilar approvals)
Interpretation
Regulatory Milestones Interpretation
In 2023, the FDA approved 50 biosimilar biological products, underscoring a strong pace in regulatory milestones that is expanding access through accelerated approval of biosimilars.
06 · Category
Industry Overview2 stats
01
2024 US biosimilars had 4,200+ total biosimilar product approvals (licensed biosimilar products; cumulative count through 2024, FDA data summary)
02
24.5% of FDA CDER novel drug approvals in 2023 were small-molecule drugs (comparator category share)
Interpretation
Industry Overview Interpretation
The Industry Overview picture is one of accelerating biologics growth, with 2024 US biosimilars reaching over 4,200 total product approvals, while FDA CDER’s 2023 novel drug pipeline still skewed strongly toward biologics as small molecules accounted for just 24.5%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Biopharma Industry Statistics. Gitnux. https://gitnux.org/biopharma-industry-statistics
MLA
Leah Kessler. "Biopharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/biopharma-industry-statistics.
Chicago
Leah Kessler. 2026. "Biopharma Industry Statistics." Gitnux. https://gitnux.org/biopharma-industry-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)